Shop Talk : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
IMA203, a TCR-T agent targeting PRAME, was safe and effective in patients with heavily pretreated melanoma.
Maurie Markman, MD, details how the precision-medicine paradigm is a highly rational platform for antineoplastic drug development.
Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.
Yuan Yuan, MD, PhD, discusses the management of node-positive breast cancer and the need for guidance surrounding the use of ctDNA in breast cancer.
A sBLA has been submitted to the FDA for subcutaneous daratumumab plus VRd in ASCT-ineligible or -deferred multiple myeloma.
Cancer care disparities exist for underrepresented groups due to limited access to healthcare, clinical trials, and cultural barriers, but solutions like telemedicine and improved communication…
Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.
AWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with initial funding
An abstract is unavailable.